+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Brain Tumor Therapeutics: Global Markets to 2023

  • ID: 4721300
  • Report
  • Region: Global
  • 161 Pages
  • BCC Research
1 of 6

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Kazia Therapeutics Ltd.
  • Navinta Llc
  • Tocagen, Inc.
  • MORE

Report Scope:

This report provides an overview of the current and future global market potential for brain tumor therapeutics. It provides a detailed analysis and information about conventional treatment options, ongoing market trends and the future direction of the market with respect to brain tumor therapy.

Inclusions

  • The report covers a detailed background of the disease state, along with epidemiological and demographic data, market segmentation by therapy (chemotherapy and targeted therapy), age group of patients (adult and pediatric brain tumors), end users (hospitals, cancer research institutes and medical universities) and a detailed regional market analysis including North America, Europe, Asia-Pacific and the rest of the world.
  • The report provides information on newer treatment opportunities and cutting-edge research on therapeutics for brain tumors. It covers various types of treatment used in the field of neuro-oncology: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.
  • A detailed analysis of agents used in the market for chemotherapy, immunotherapy and targeted therapy, as well as a pipeline analysis of newer molecules and therapeutics is covered in the report.
  • A comprehensive analysis of market dynamics in the industry and current market trends are described in the report, along with the competitive landscape and discussion about key market players in the field of brain tumor therapeutics, where market strategies of these players are studied and described. The report includes a patent analysis of brain tumor therapeutics.
  • The report concludes with company profiles of key players in the development and commercialization of brain tumor therapeutics.
  • A separate chapter on emerging trends and breakthrough technologies in the field of neuro-oncology has been included in this report.

Exclusions

Excluded from this report are the market size for equipment used in radiotherapy, surgical equipment and supplies and market size for drugs used for the symptomatic management of cancer (anti-epileptics, anti-emetics and hormonal medications). This report also excludes market size for immunotherapy. This is not a proven treatment for brain tumors and is currently being developed in research and clinical trials.

Market values are provided for 2017 as base year, 2018 and forecast through 2023. Estimated values are based on manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The Report Includes:

  • 20 data tables and 40 additional tables
  • Comprehensive overview of the global market for brain tumor therapeutics within the pharmaceutical industry
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Impact analysis of major drivers and restraints, and regional dynamics of the global brain tumor therapeutics markets and current trends within the industry
  • Company profiles of prominent players in the market, including Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis International AG
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Kazia Therapeutics Ltd.
  • Navinta Llc
  • Tocagen, Inc.
  • MORE

Chapter 1 Introduction

  • Scope of Report
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Information Sources and Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

  • Key Findings

Chapter 3 Disease Background and Overview

  • Introduction
  • What is Cancer?
  • Cancer Drivers
  • Cancer Staging
  • Disease Background
  • Brain Tumor Statistics
  • Human Brain Function
  • Causes of Tumor Development
  • Mechanism of Tumorigenesis
  • Types and Classification of Brain Tumors
  • Diagnosis of Brain Tumors
  • Magnetic Resonance Imaging (MRI)
  • Magnetic Resonance Spectroscopy (MRS)
  • Tissue Sampling/Biopsy/Surgical Removal of Tumor
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET) or PET-CT Scan
  • Cerebral Arteriogram
  • Lumbar Puncture or Spinal Tap
  • Myelogram
  • Molecular Testing
  • Neurological, Vision and Hearing Tests
  • Neurocognitive Assessment
  • Electroencephalography (EEG)
  • Evoked Potentials
  • Recurrence of Brain Tumors and Management
  • Brain Tumor Metastases and Management
  • Cognitive Challenges
  • Pain Management
  • Treatment Modalities
  • Surgery
  • Neurosurgery
  • Emerging Treatments in Neurosurgery
  • Radiotherapy
  • New and Emerging Treatments in Neuro-radiotherapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

Chapter 4 Market Dynamics

  • Introduction
  • Market Drivers
  • Increasing Global Incidence of Brain Cancer
  • Early Cancer Detection
  • Research Initiatives
  • R&D Collaborations
  • Increase in Oncology Spending
  • Accelerated Approvals for Drugs Used in Rare Diseases
  • Market Restraints
  • Lack of Effective Treatment Options for Brain Tumors
  • High Cost
  • Low Screening
  • Current Market Trends
  • Immunotherapy
  • Combination Therapy
  • MRI-Guided Laser Surgery
  • Palliative Therapy
  • 3D Radiation Therapy
  • Precision Medicine and Companion Diagnostics
  • Polymer Wafer Implants
  • Tumor Treating Fields (TTF)

Chapter 5 Market Breakdown by Therapy

  • Introduction
  • Chemotherapy
  • Overview
  • Principle of Chemotherapy
  • BBB and Chemotherapy
  • Chemotherapeutic Agents
  • Side Effects of Chemotherapy
  • New Developments
  • Market Overview
  • Market Size and Forecast
  • Targeted Therapy
  • Introduction
  • Precision Medicine in Cancer
  • Types and Methods of Targeted Therapy
  • Drug Delivery Systems for Targeted Therapeutics
  • FDA-Approved Targeted Therapeutics
  • New Developments
  • Market Overview
  • Market Size and Forecast
  • Immunotherapy
  • Introduction
  • Immunotherapeutic Agents
  • New Developments
  • Market Overview

Chapter 6 Market Breakdown by Patient Age

  • Introduction
  • Overview
  • Treatment Options
  • Market Overview
  • Market Size and Forecast

Chapter 7 Market Breakdown by End User

Chapter 8 Market Breakdown by Region

  • Introduction
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9 Emerging Technologies and Future Trends

  • Introduction
  • Cancer Vaccines
  • Nanomedicine
  • Stem Cell Therapy
  • Photodynamic Therapy
  • Focused Ultrasound Therapy
  • Radiomics and Pathomics
  • CRISPR
  • Artificial Intelligence
  • Advancements in Genomics and Personalized Medicine

Chapter 10 Clinical Research in Brain Tumor Therapeutics

  • Introduction
  • The Drug Development Process
  • Drug Discovery
  • Early Formulation Studies
  • Pre-Clinical Safety Studies
  • Clinical Trials
  • Regulatory Review
  • Post-Marketing Surveillance
  • Research Initiatives
  • Defeat GBM Research Collaborative
  • Cancer Moonshot
  • End Brain Cancer Initiative
  • Brain Cancer Translational Research Initiative
  • Pediatric Brain Tumor Initiative
  • GLIOTRAIN
  • GBM Agile
  • Clinical Trials and Experimental Treatments

Chapter 11 Patent Review

  • Introduction
  • Significant Patents

Chapter 12 Competitive Landscape and Market Strategies

  • Introduction
  • Major Players and Market Share Analysis
  • Market Strategies Employed, by Major Players
  • Research and Development
  • Patent Exclusivity
  • Mergers and Acquisitions (M&A)
  • New Developments
  • Porter's Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat from New Entrants
  • Threat from Substitutes
  • Market Competition

Chapter 13 Regulatory and Reimbursement Landscape

  • Introduction
  • Drug Development Regulations
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Asia Pacific
  • ROW
  • Reimbursement Landscape

Chapter 14 Company Profiles

  • ASTRA ZENECA PLC
  • Business Overview
  • BRISTOL-MYERS SQUIBB CO.
  • Business Overview
  • Financial Information
  • Products and Services
  • Development and Strategies
  • CURTANA PHARMACEUTICALS, INC.
  • Business Overview
  • DEL MAR PHARMACEUTICALS, INC.
  • Business Overview
  • EISAI CO. LTD.
  • Business Overview
  • EMCURE PHARMA
  • Business Overview
  • F. HOFFMANN-LA ROCHE LTD.
  • Business Overview
  • Financial Information
  • Products and Services
  • Development and Strategies
  • Business Highlights
  • FRESENIUS KABI ONCOLOGY LTD.
  • Business Overview
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • Business Overview
  • ITEOS THERAPEUTICS
  • Business Overview
  • KAZIA THERAPEUTICS LTD.
  • Business Overview
  • MERCK & CO., INC.
  • Business Overview
  • Financial Information
  • Products and Services
  • Development and Strategies
  • Business Highlights
  • NAVINTA LLC
  • Business Overview
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • Business Overview
  • Products and Services
  • Development and Strategies
  • Business Highlights
  • NORTHWEST BIOTHERAPEUTICS, INC.
  • Business Overview
  • NOVARTIS INTERNATIONAL AG
  • Business Overview
  • Financial Information
  • Products and Services
  • Development and Strategies
  • Business Highlights
  • TOCAGEN, INC.
  • Business Overview
  • UNITED THERAPEUTICS CORP.
  • Business Overview

Chapter 15 Appendix: Acronyms

List of Tables
Summary Table: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
Table 1: WHO Grading of Brain Tumors
Table 2: WHO Grading of Select Brain Tumors
Table 3: Survival Rates for Common Adult Brain and Spinal Cord Tumors, 2017
Table 4: Brain Structures and Functions
Table 5: WHO Classification of Brain Tumors, 2016
Table 6: Karnofsky Performance Scale
Table 7: Specific Types of Brain Tumor Metastasis
Table 8: Parts of the Brain Related to Major Cognitive Functions
Table 9: Timeline of Significant Developments in Radiotherapy, 1898-2006
Table 10: Rare/Orphan Drug Criteria: Selected Regulatory Organizations
Table 11: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
Table 12: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 13: Dosage and Administration of Temozolomide for Brain Tumors
Table 14: Current Brain Tumor Clinical Trials: Temozolomide
Table 15: Current Brain Tumor Clinical Trials involving Lomustine
Table 16: Current Brain Tumor Clinical Trials involving Carmustine
Table 17: PCV Regimen: Brain Tumor Chemotherapy
Table 18: Global Market for Brain Tumor Chemotherapy, by Region, Through 2023
Table 19: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 20: Monoclonal Antibodies
Table 21: Small Molecule Monoclonal Antibodies
Table 22: Current Brain Tumor Clinical Trials involving Bevacizumab
Table 23: Current Brain Tumor Clinical Trials involving Everolimus
Table 24: Global Market for Brain Tumor Targeted Therapy, by Region, Through 2023
Table 25: Current Brain Tumor Clinical Trials: Immunotherapy
Table 26: Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2023
Table 27: Hereditary Factors: Pediatric Brain Tumors
Table 28: Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2023
Table 29: Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2023
Table 30: Global Market for Brain Tumor Therapeutics Market, by End User, Through 2023
Table 31: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, Through 2023
Table 32: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, Through 2023
Table 33: Global Market for Brain Tumor Therapeutics in Universities, by Region, Through 2023
Table 34: Global Market for Brain Tumor Therapeutics , by Region, Through 2023
Table 35: North American Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 36: European Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 37: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 38: Drug Development
Table 39: Selected Current Phase I Brain Tumor Clinical Trials
Table 40: Selected Current Phase II Brain Tumor Clinical Trials
Table 41: Selected Current Phase III Brain Tumor Clinical Trials
Table 42: Patent Review of Novel Compounds and Drug Delivery in Brain Tumors, February 2017 to August 2018
Table 43: Patent Review of Therapeutic Agents for Brain Tumors, January 2017 to August 2018
Table 44: Patent Review of Combination Therapies in Brain Tumors, September 2017 to September 2018
Table 45: Patent Review of Immunotherapies for Brain Tumors, December 2016 to July 2018
Table 46: Patent Review of Diagnosis and Biomarkers in Brain Tumors, January 2017 to September 2018
Table 47: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 48: Current Orphan Drug Designations for Brain Tumors
Table 49: Bristol-Myers Squibb: Revenue 2016 and 2017
Table 50: Bristol-Myers Squibb: Brain Tumor Pharmaceuticals
Table 51: Opdivo Approvals, 2017
Table 52: F. Hofmann-La Roche: Revenue 2016 and 2017
Table 53: F. Hofmann-La Roche: Brain Tumor Pharmaceutical Drugs
Table 54: Merck & Co., Inc.: Revenue 2016 and 2017
Table 55: Merck & Co., Inc.: Brain Tumor Pharmaceutical Drugs
Table 56: NextSource Biotechnology LLC: Brain Tumor Therapeutics
Table 57: Novartis: Revenue 2016 and 2017
Table 58: Novartis: Brain Tumor Pharmaceuticals
Table 59: Important Acronyms Related to Brain Tumor Therapeutics Used in This Report

List of Figures
Summary Figure: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
Figure 1: Percentage Share of Global Cancer Incidence, by Type, 2018
Figure 2: Percentage Share of Global Cancer Incidence, by Region, 2018
Figure 3: Hallmarks of Cancer
Figure 4: Five Year Relative Survival at Diagnosis, by Stage, 2014-2018
Figure 5: Goals of Surgical Treatment for Brain Tumors
Figure 6: Global Expenditures on Oncology Drugs, by Country/Region, 2013-2017
Figure 7: Projected Global Expenditures on Oncology Drugs, by Country/Region, 2020
Figure 8: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
Figure 9: Global Market for Brain Tumor Chemotherapy, by Region, 2017-2023
Figure 10: Targeted Therapy Types
Figure 11: Global Market for Brain Tumor Targeted Therapy, by Region, 2017-2023
Figure 12: Global Market for Brain Tumor Therapeutics, by Patient Age, 2017-2023
Figure 13: Percentage Share of Common Adult Brain Tumor Incidence, by Type, 2017
Figure 14: Percentage Share of Common Pediatric Brain Tumor Incidence, 2017
Figure 15: Differences: Adult and Pediatric Brain Tumors
Figure 16: Etiology: Pediatric Brain Tumors
Figure 17: Global Market for Adult Brain Tumor Therapeutics, by Region, 2017-2023
Figure 18: Global Market for Pediatric Brain Tumor Therapeutics, by Region, 2017-2023
Figure 19: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, 2017-2023
Figure 20: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, 2017-2023
Figure 21: Global Market for Brain Tumor Therapeutics in Universities, by Region, 2017-2023
Figure 22: Global Incidence of Brain Tumors, 2018-2040
Figure 23: Global Market for Brain Tumor Therapeutics Market, by Region, 2017-2023
Figure 24: North American Incidence of Brain Tumors, 2018-2040
Figure 25: North American Market for Brain Tumor Therapeutics, 2017-2023
Figure 26: North American Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 27: European Incidence of Brain Tumors, 2018-2040
Figure 28: European Market for Brain Tumor Therapeutics, 2017-2023
Figure 29: European Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 30: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 31: Asia-Pacific Market for Brain Tumor Therapeutics, 2017-2023
Figure 32: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 33: ROW Market for Brain Tumor Therapeutics, 2017-2023
Figure 34: Pharmaceutical Drug Development
Figure 35: Current Clinical Trials, by Phase, 2018
Figure 36: Major Market Players Share in Brain Tumor Therapeutics Market, 2017
Figure 37: NIH Funding for Brain Cancer R&D, 2016-2018
Figure 38: R&D Expenditure of Top 3 Players in Brain Tumor Therapeutics, 2017
Figure 39: Bargaining Power of Buyers in the Brain Tumor Therapeutics Industry
Figure 40: Bargaining Power of Suppliers in the Brain Tumor Therapeutics Industry
Figure 41: Threat from New Entrants in the Brain Tumor Therapeutics Industry
Figure 42: Threat from Substitutes in the Brain Tumor Therapeutics Industry
Figure 43: Market Competition in the Brain Tumor Therapeutics Industry
Figure 44: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 45: Bristol-Myers Squibb: Net Sales, by Region/Country, 2017
Figure 46: Bristol-Myers Squibb: R&D Expenditure, 2016 and 2017
Figure 47: Roche Top 5 Pharmaceutical Drugs, by Sales Revenue, 2017
Figure 48: Avastin: Sales Revenue, 2016 and 2017
Figure 49: F. Hofmann-La Roche: Revenue Share, by Business Segment, 2017
Figure 50: F. Hofmann-La Roche: Revenue, by Region, 2015-2017
Figure 51: Roche Product Pipeline, by Disease Area, 2017
Figure 52: Novartis: Net Sales, by Division, 2017
Figure 53: Novartis: Net Sales, by Region, 2017

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Kazia Therapeutics Ltd.
  • Navinta Llc
  • Tocagen, Inc.
  • MORE

The mortality rate of brain cancer in both the adult and the pediatric population is very high. According to the Global Cancer Observatory, around 241,037 patients are expected to die globally due to brain tumors in 2018. The high recurrence rate of malignant brain tumors is due to the reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers. The median duration of patient survival of brain tumors is estimated to be between 12 and 18 months with maximal treatment. Only 2-5% of patients survive for more than three years. Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by the lack of specific therapies for the brain and retardation of drug delivery to brain tumors due to the presence of the blood-brain barrier (BBB). Therefore, there is a substantial need for novel and effective therapeutic drugs and strategies that prolong survival and improve the quality of life for brain tumor patients.

The development of combination therapies involving surgery, radiotherapy and chemotherapeutic agents, along with innumerable ongoing research and clinical trials for evolving targeted therapies and novel immunotherapeutic strategies are expected to offer promising alternatives to conventional treatments in the future. In addition, novel methods of drug delivery such as such as nano-particle mediated drug delivery, super selective intra-arterial cranial infusions and chemotherapeutic wafers help to further extend the lifespan of patients diagnosed with this disease and significantly improve the overall quality of survival. Immune response-based strategies like monoclonal antibodies, brain cancer vaccines, and oncolytic viral therapies are in clinical trials and are expected to offer enormous potential for growth in this market. In coordination with conventional and adjunct therapies, immune-response based strategies will result in a sizable expansion of the brain tumor therapeutics market in the future.

Note: Product cover images may vary from those shown
5 of 6
  • Astra Zeneca Plc
  • Bristol-Myers Squibb Co.
  • Curtana Pharmaceuticals, Inc.
  • Del Mar Pharmaceuticals, Inc.
  • Eisai Co. Ltd.
  • Emcure Pharma
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi Oncology Ltd.
  • Immunocellular Therapeutics Ltd.
  • Iteos Therapeutics
  • Kazia Therapeutics Ltd.
  • Merck & Co., Inc.
  • Navinta Llc
  • Nextsource Biotechnology Llc
  • Northwest Biotherapeutics, Inc.
  • Novartis International Ag
  • Tocagen, Inc.
  • United Therapeutics Corp.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4721300
Adroll
adroll